How Novo Nordisk makes its weight-loss drug Wegovy
Send a link to a friend
[November 01, 2023]
By Maggie Fick
LONDON (Reuters) - Novo Nordisk is spending billions of dollars to boost
output and ease shortages of its hugely popular, highly effective
weight-loss medicine Wegovy.
The Danish drugmaker, which reports its third-quarter results on Nov. 2,
has warned U.S. demand will continue to outpace supplies of the weekly
self-injection into 2024.
Novo depends upon a number of companies to help produce Wegovy, but it
has released scant details on its supply chain for the weight-loss
medicine and its diabetes drug Ozempic containing the same active
ingredient.
Here are the details of the manufacturing supply chain, based on public
statements by Novo and Reuters' reporting:
ACTIVE PHARMACEUTICAL INGREDIENT (API)
The active pharmaceutical ingredient (API) contained in Wegovy is called
semaglutide. Novo says that it produces all of the API for Wegovy at its
facilities in Denmark.
FILL-FINISH
Novo has hired Catalent, a large U.S. contract drug manufacturer, to
fill injection pens for Wegovy at two of that company's plants: in
Brussels and in Bloomington, Indiana.
Novo has also hired another U.S. firm, Thermo Fisher, as a Wegovy pen
filler. That company is performing the work at its factory in
Greenville, North Carolina.
It has said it will sign up a third by the end of the year but has not
identified the company. Thermo is converting a building that makes
tablets and pills at the Greenville site to do sterile fill-finish work
instead, a company spokesperson told Reuters last week.
ASSEMBLY AND PACKAGING
At its most recent capital markets day, in March 2022, Novo said it
assembled and packaged Wegovy at its own facilities.
[to top of second column]
|
A selection of injector pens for the Wegovy weight loss drug are
shown in this photo illustration in Chicago, Illinois, U.S., March
31, 2023. REUTERS/Jim Vondruska/Illustration/File Photo
In September, Reuters reported that
Novo had hired U.S. private company PCI Pharma Services to handle
some assembly and packaging of the drug.
Assembling the pens after a glass cartridge is filled with Wegovy is
the final stage of manufacturing before it is shipped.
COMPONENTS
The Wegovy injection pens for the U.S. market slightly differ from
those sold in the European markets including Norway, Denmark,
Germany and UK, where it has so far launched.
The pen for Europe uses the so-called FlexTouch device and contains
four doses per pen, instead of one in the U.S. pen.
Both pen devices contain a number of components. They include,
depending on the device: a glass cartridge or a glass syringe, a
pre-filled plastic pen, a needle shield, and a rubber plunger.
Swiss medical technology company Ypsomed in September announced a
long-term supply deal with Novo for autoinjectors, another component
contained in the pens.
Several large companies have said they are making these components
for companies manufacturing injection drugs from the GLP-1 receptor
class to which Wegovy belongs.
These companies include West Pharmaceutical Services, Stevenato
Group SpA, Gerresheimer and SCHOTT Pharma.
(Reporting by Maggie Fick; Editing by Josephine Mason and Tomasz
Janowski)
[© 2023 Thomson Reuters. All rights
reserved.]This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content.
|